Boehringer Ingelheim Animal Health invests up to 13 % of its
net sales into R & D each year.
By international industry standards this can be regarded as high percentage.
Our focus is primarily on the development of new pharmaceutical solutions for small animals and preventive measures for the
food producing animals sector. These efforts have culminated in several interesting projects in the current pipeline and good progress in the development of innovative pharmaceutical molecules.
